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Functional modiﬁcation of transcription regulators may lead to developmental changes and phenotypical diﬀerences between
species. In this work, we study the inﬂuence of alternative splicing on transcription factors in human and mouse. Our results
show that the impact of alternative splicing on transcription factors is similar in both species, meaning that the ways to increase
variability should also be similar. However, when looking at the expression patterns of transcription factors, we observe that they
tend to diverge regardless of the role of alternative splicing. Finally, we hypothesise that transcription regulation of alternatively
splicedtranscriptionfactorscouldplayanimportantroleinthephenotypicaldiﬀerencesbetweenspecies,withoutdiscardingother
phenomena or functional families.
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1.Introduction
Some years ago the hypothesis that morphological dif-
ferences between species are due to changes in the gene
regulatory regions was proposed [1]. Recent advances in
the development ﬁeld are providing supporting evidences
even when comparing relatively remote species [2] and their
interpretation within an evolutionary context has lead to
creation of the evo-devo ﬁeld. An important part of the
research within this ﬁeld is focused on the comparison of
gene regulatory regions [2]. However, less attention has
been devoted to explore the role of transcription factors
(TFs). Regulation of the activity of transcription factors is a
complex process [3] including a broad range of intrinsic and
environmental factors. This is particularly relevant within
the context of development and evolutionary research, since
control of the amount of TFs, at precise locations and
times, may constitute a ﬁner alternative to the more drastic
presence/absence of TFs binding sites.
Among the mechanisms modulating the activity of
TFs the role of alternative splicing (AS) has been well
documented in the recent years [3–5]. Indeed, diﬀerent
studies have shown that AS of TFs results in regulatory
isoforms [3, 6–9] that can be tissue- or development stage-
speciﬁc [4, 10–13] and show cell distribution variation
[14]. In general, the biological eﬀect of AS on TFs can
be easily interpreted if we consider the fact that TFs are
commonly large proteins with a modular composition [4,
7]. TFs domains have diﬀerent roles related to the main
function of TFs: DNA binding, dimerization and function
regulation. DNA binding domains are required to recognize
target sequences; dimerization domains allow the building of
dimers or oligomers which are the biological unit of many
TFs; and regulatory domains are used to detect external2 Comparative and Functional Genomics
stimulus or signals from transduction pathways. Therefore,
loss of one of these domains will be accompanied by the
loss of one of these functional properties, thus resulting
[3, 15–18] in transcripts that either (i) lack the original
activity, (ii) show and increase or decrease in this activity,
or (iii) act as dominant negative of the fully-functional
isoform, having an antagonistic eﬀect. Obviously, the nature
of the regulation associated to AS depends on the domains
involved. However, it is important to notice that a partial
deletionorsubstitutioncanalsoleadtoalossormodiﬁcation
of domain functionality [19, 20].
Bioinformatics research has widely studied AS using
severalapproaches,contributingtoshapeourpresentviewof
the functional changes caused by this phenomenon [21–29].
In the case of TFs, work from diﬀerent authors has focused
in the study of AS mechanisms of cancer-related genes [30],
in the properties of speciﬁc domains in AS [31], and in the
role of AS of TFs in diﬀerent species [10]. Among other
facts, it has been established that human and mouse have
diﬀerent TFs variants [31] and that TFs seem to be more
frequently spliced, creating tissue-speciﬁc isoforms with
diﬀerent domain architectures [10]. In spite of their growing
amount, the view provided by these studies is still incom-
plete, and important aspects related to the variability gener-
ated by AS and its interspecies conservation remain unclear.
In this article we compare how AS of TFs varies between
human and mouse, two species with clear morphological
diﬀerences, focusing on some characteristics related to the
generation of regulatory mechanisms. In addition, we also
compared the expression levels of orthologous TFs to see
whether there are substantial expression diﬀerences between
both species. Our results indicate that human and mouse use
similar mechanisms to regulate the action of TFs. We also
ﬁnd, for a population of human-mouse orthologs, that TFs
tend to show diverging gene expression changes not related
to the presence of AS.
2.MaterialsandMethods
2.1. Data. TFs and enzymes sequences and position of
variable regions were obtained from SwissProt [32]. The
most important point in the bioinformatics studies is
the election of the dataset. There are several options: (1)
manually curated databases; (2) automatically-annotated
databases and (3) mining of publicly available experimental
data, all having strengths and weaknesses [33]. Curated
databases contain the most reliable information, but have a
small coverage. Automatic annotation of databases increases
the amount of data, but as the annotations are transferred
by homology their reliability depend on the used thresholds.
Finally, the public repositories contain a huge amount of
unprocesseddata.Obviously,allachievedconclusionsshould
be nuanced according to the used dataset. As our analysis
relied in the correlation between alternative regions and
functional domains, we thought that it was crucial to analyse
real isoforms, which are provenly transcribed and translated,
instead of putative peptides. Consequently, we chose the
database containing less artefacts [34]. In addition, although
wemissedseveralisoformsinouranalyses,thegeneraltrends
shouldnotbeimportantlyaﬀected,aswefoundinaprevious
study [26].
2.2. Similarity of TFs. We compared all TFs isoforms using
the CD-HIT software [35]. This tool clusters all sequences at
a given identity threshold.
2.3. Domain Predictions. Functional domains from SMART
[36] and Pfam [37] were identiﬁed with RPS-BLAST (a
PSI-BLAST variant [38]) using 0.02 as E-value and the low
complexity ﬁlter. When the domain annotation for these
two databases overlapped without completely coinciding,
we chose the longest domain assignment and discarded the
shortest if at least 60% of it overlapped with the longest.
2.4. Precision of AS Eﬀects on TFs. F o re a c hA Sm o d i ﬁ c a t i o n ,
we took the N- and C-terminal positions of the variable
region and the N- and C-terminal boundaries of the related
functional domains, if any. We ordered the four positions
and calculated the precision as the ratio between the residues
being both functional and alternatively spliced and all the
residues being either in the functional domain or the AS
region. A precision close to 1 meant that AS was almost
coincident with functional domain boundaries, whereas a
low precision showed a lower correlation.
2.5. TFs Expression Patterns. Expression data for human
and mouse genes were retrieved from the SymAtlas server
(http://symatlas.gnf.org,n o wa thttps://biogps.gnf.org/)
(human: GNF1H; mouse: GNF1M) [39]. These data did not
contain isoform expression, but all isoforms were grouped.
This fact was useful to our goal, because we were not
interested in the expression of the equivalent isoforms, but
in the eﬀect of the ability of alternatively splice genes on the
expression pattern of orthologs.
We analysed 559 TFs from 30 common tissues (mouse
spinal cord data was the average of upper and lower
spinal chord ones). This dataset was divided in three sets,
depending on the presence of AS, as follows: (a) a set of 123
TFs for which both orthologs had AS; (b) a set of 109 TFs
which were alternatively spliced in one species but not in the
other; and ﬁnally (c) a set of 327 TFs with no AS neither in
humannorinmouse.Inaddition,weanalysedtheexpression
pattern of 1923 enzymes so as to study if TFs had some kind
of speciﬁc features.
Gene expression tissue patterns were compared using
the Pearson’s correlation, following similar studies [40–43].
High correlations mean that genes have similar expression
patterns, whereas low correlations indicate variations due to
tissue-speciﬁc expression. As suggested by Liao and Zhang
[43], we used relative abundance instead of signal intensity
measured from the microarrays. Signal intensity does not
quantify the abundance of mRNA in the sample, is diﬀerent
for each experiment and is inﬂuenced by many factors. On
the contrary, the relative abundance normalises the values
within each experiment: brieﬂy, each expression level is
divided by the sum of all the signals in the experiment.Comparative and Functional Genomics 3
Table 1: Summary of AS data for human and mouse TFs.T h e
results for ALL GENES are those obtained analysing all entries
in SwissProt. Each TFs dataset must be compared with the same
species ALL GENES dataset.
TFs All genes
Human Mouse Human Mouse
No. of genes 1077 737 12946 10031
% AS+ 29.4 26.1 26.9 17.6
No. of isoforms/gene 3.0 2.9 2.8 2.7
This normalisation allows comparison of results of diﬀerent
experimental results. When several replicas were available
for a given experiment we averaged the expression data.
In addition, comparison between these replicas was utilized
to obtain a control of the reproducibility of the results. In
absence of alternative experimental validation, this control
ensures that the possible diﬀerences are not due to the
variance between experiments.
3. Results andDiscussion
3.1. Diversity of TFs. Since the publication of the human
genome it was suggested that rate diﬀerences in AS could
be associated to phenotypic diﬀerences between organisms
[44]. In the case of TFs, Taneri and colleagues [10]h a v e
recently shown that for mouse the percentage of genes
with AS is higher for TFs than for other proteins. In our
case (Table 1) we found that this was the case for mouse
(T-test P-value ∼0) as well as for human (T-test P-value
∼0.04). This means that the higher rate of AS in TFs could
be a general feature. In addition, the average number of
isoforms per gene was similar in both species. The actual
percentages of genes having AS were diﬀerent from those
obtained by Taneri and colleagues (62% and 29% of TFs loci
and all loci, resp.) [10], because they build their database
using a computational algorithm, whereas we relied only on
experimentally validated protein isoforms. The important
point is that the biases aﬀecting the manual or automatic
annotation of AS would aﬀect all loci. Thus, independently
of the presented percentages, the fact is that TFs genes
have a signiﬁcantly higher rate of AS. The rate diﬀerences
between human and mouse could be real or simply due to
the diﬀerent coverage of the two species [45, 46].
Additionally,welookedatthesimilarityofTFs.Giventhe
existence of structural and evolutionary restrictions [47, 48]
and that the number of functional domains is limited; we
expected that many TFs would share a big part of their
sequence.However,weobservedthatveryfewTFshadahigh
identitypercentageneitherinhumannorinmouse(Table 2).
Moreover, just one third or one quarter of the isoforms
was at least 40% identical, meaning that the majority of
TFs probably did not have the same functionality [49].
The latter result was not diﬀerent from that obtained with
the control; however, control included all human non-TFs
proteins, which could be very diﬀerent proteins. According
totheliterature,nobigdiﬀerenceswouldbeexpectedifusing
mouse proteins instead of the human dataset as a control
Table 2: Similarity among TFs. The table shows the percentage of
TFs isoforms which share an identity percentage. Control includes
all the human non-TFs protein sequences.
Control Human Mouse
No. of genes 10937 1077 737
No. of protein sequences 17026 1702 1093
90% 0.04 0.01 0.01
80% 0.07 0.02 0.02
70% 0.10 0.07 0.04
60% 0.16 0.13 0.08
50% 0.22 0.22 0.15
40% 0.31 0.34 0.23
[26, 27, 45, 50, 51]. These results suggest that the role of
AS in the slight regulation of TFs is almost unique, as gene
duplicatesaresodivergentthattheyhardlycouldplaysimilar
roles [26].
3.2. AS Eﬀects on TFs Functional Domains. Next we studied
how AS aﬀects domain composition in TFs, a feature directly
related to the regulation of protein function in general [26,
27, 52–54] and to that of TFs in particular [4, 5, 16, 55].
Analysing TFs with AS from our dataset, we found that in
28% and 18% of human and mouse TFs at least one isoform
showeddomaincompositionchanges;andfromthediﬀerent
domain types present, 59% in human and 68% in mouse
were aﬀected by alternative splicing. These data suggest that
both organisms use AS to regulate the action of TFs in a
similar way.
As the eﬀect of AS upon the TFs depend on the aﬀected
functional domains, it is important to know whether the
process is random-like. In our case we ﬁrst observed that AS
did not aﬀect all possible domains. And second, we found
thatamongthoseaﬀected,notallwereaﬀectedwiththesame
frequency, in accordance with what was found by Liu and
Altman [25] when considering the whole proteome. More-
over, we see that the most aﬀected domains (HOX, HOLI,
HLH, and PHD) are the same and with similar percentages
in both species. The only exception was the (Krueppel-
associated box) KRAB domain, which is frequently aﬀected
in human and not in mouse, probably due to the absence
of mouse orthologs in our dataset. In accordance with
Taneri and colleagues [10], we ﬁnd that AS frequently aﬀects
DNA-binding domains in both species. For example, the
most frequently aﬀected domain common to both species is
HOX, the homeobox domain responsible of DNA binding
in transcription factors. However, we found that AS may
also aﬀect domains with other biochemical properties. This
is the case of the common second most frequently aﬀected
domain, HOLI, a hormone-binding domain present in
nuclear hormone receptors. Also a frequently spliced-out
domain, PHD, is involved in protein-protein interactions
and/or interactions with chromatin.
Previous studies on the eﬀect of AS on functional
domainsindicatethatASshowsabiastowardsencompassing
whole domains [29, 56]. However, as emphasized by Zavolan4 Comparative and Functional Genomics
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Figure 1: The four possible types of overlap between AS (coloured
in red) and protein domains (boxes).
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Figure 2: Precision of AS eﬀect on TFs functional domains. Bar
histograms show results for the observed frequencies, whereas the
lines show distribution for the expected frequencies at random.
Human (blue) and mouse (red) results are shown.
and van Nimwegen [57] there are also many cases in
which AS only aﬀects part of the protein domain. To
explore what happened in the case of TFs, we measured
the overlap between AS and domain boundaries. Firstly, we
measured the precision of AS eﬀect on TFs. Surprisingly;
results show a random distribution either in human or
mouse (Figure 1). As alternative splicing is determined by
gene structure and cannot occur wherever by chance, we
reﬁned our analysis. More precisely we considered four
diﬀerentsituations(Figure 2):(I)ASanddomainboundaries
coincide exactly; (II) the spliced-out region spreads over the
whole domain and surrounding sequence; (III) the spliced-
out region is completely included within the domain and
(IV) there is only a partial overlap between the spliced-
out region and the functional domain. A high frequency
of type I cases would mean a positive selection towards
the co-evolution of AS and functional domains. On the
contrary, types II, III, and IV suggest that any kind of
correlation, if existing, would be weak. The results obtained
are shown in Table 3. We see that the ﬁrst situation was
never observed, in accordance with the very low probability
of exact coincidence between AS and domain boundaries.
However, the three remaining situations were found in
both species with comparable ratios—including diﬀerences
between observed and expected frequencies—indicating that
the functional regulation of TFs by AS is reached by similar
mechanisms in both species.
3.3. Expression of Orthologous TFs. All these results point to
a coincidence between human and mouse in the regulation
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Figure 3: Comparison of the expression pattern of human and
mouse ortholog TFs. The ﬁgure shows the distribution of Pearson’s
correlation values for the three following comparisons between
human and mouse ortholog TFs: TFs having AS in both species
(blue), TFs having AS in only one species (green) and TFs with
no AS in any of the two species (yellow). In addition, it shows
distribution for enzymes (purple) and replica’s control (red). We
calculated 95% conﬁdence intervals for each bar on frequency
histograms assuming the independence hypothesis [58].
Table 3: AS eﬀects on functional domains. For each of the species are
shown the observed and the expected (in parenthesis) frequencies.
Human Mouse
Type I 0.00 (0.00) 0.00 (0.00)
Type II 0.36 (0.20) 0.24 (0.14)
Type III 0.23 (0.42) 0.43 (0.47)
Type IV 0.41 (0.38) 0.33 (0.39)
of TFs function by AS. Finally, we studied whether the
presence/absence of AS may result in diﬀerences in TFs
expressionpattern.Inourstudyweconsideredthreediﬀerent
situations: (a) the TFs gene has AS in both species, (b)
the TFs gene has AS in only one species; and (c) no AS
was observed for the TFs genes in neither species. We
compared TFs expression with that from enzymes, in order
to have an external group. Because array data may show
large ﬂuctuations, we also used as a control experimental
replicas for each TFs. When looking at the results (Figure 3)
we can see that the replica’s control has a high correlation
in the expression distribution meaning that the diﬀerent
experiments were consistent. More interestingly, we observe
that the distributions for the three TFs human-mouse
comparisons are clearly diﬀerent from that of the replica’s
control, whereas they are similar to that of enzymes. This
points that, in general, human and mouse orthologous genes
tend to have divergent tissue expression patterns and that
TFs are no exception, even if the majority of their equivalent
functional domains (either constitutive or alternative) are
identical. This means that human and species do not use
comparatively the same TFs in the same tissues. Finally, the
trend does not depend on whether the TFs has AS, since the
distributions for the three possible situations are essentially
the same; thus, discarding the exclusive role of the speciﬁc
isoforms in the apparition of the expression divergence.
The uncoupling between AS and transcription regulation
suggests they provide two independent levels of control of
TFs products.Comparative and Functional Genomics 5
Overall, our results indicate that rather than AS alone, a
combination of AS and regulation at the transcription level
may determine the nature and ﬁnal amount of product for
TFs [59, 60]. This suggests that in addition to changes at
promoter regions, regulation of TFs activity might also play
animportantroleinthoseprocessesthatresultinphenotypic
diﬀerences between species. Importantly, this does not
discard the role of other functional families or alternative
phenomena, such as posttranslational modiﬁcations [61],
in the apparition of interspecies diﬀerences. Additional
experimental studies should be done in the future to test the
validity of these hypotheses.
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